Figure 2.

Rgs2 is highly expressed in CD24Low Sca-1- 33A10- mouse mammary basal/myoepithelial and human breast myoepithelial cells. (a) Flow cytometric staining profile of mouse mammary cell preparations stained with anti-Sca-1 and anti-CD24 antibodies together with either a nonspecific rat IgG and anti-rat-FITC or 33A10 and anti-rat FITC. The nonspecific IgG and 33A10 staining profiles of the CD24Low Sca-1- basal/myoepithelial cells (33A10-), CD24High Sca-1- (Esr1-) luminal cells (33A10High) and CD24High Sca-1+ (Esr1+) luminal cells (33A10Low) [14] are indicated. (b) Mean fold differences ± 95% confidence limits in RNA abundance for the Rgs2 gene in CD24Low Sca-1- basal/myoepithelial, CD24High Sca-1- (Esr1-) luminal epithelial and CD24High Sca-1+ (Esr1+) luminal epithelial mouse mammary cells (n = 3 for all samples) [14]. The dotted lines indicate the 95% confidence limits of the comparator sample. All samples show a significant difference to the comparator (**P < 0.01). The basal myoepithelial cells also have a significantly higher level of Rgs2 expression than either of the two luminal populations. (c) Mean fold differences ± 95% confidence limits in expression levels for the RGS2 gene in myoepithelial and luminal epithelial human breast cells compared with human breast fibroblasts (comparator). See Materials and methods for details of the samples. The dotted lines indicate the 95% confidence limits of the comparator sample. Both samples show a significant difference to the comparator (**P < 0.01) and the myoepithelial cells have a significantly higher level of RGS2 expression than the luminal cells.

Smalley et al. Breast Cancer Research 2007 9:R85   doi:10.1186/bcr1834
Download authors' original image